S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
Launched by SWOG CANCER RESEARCH NETWORK · Jun 23, 2004
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES: I. Investigate the ability of the Southwest Oncology Group Melanoma Committee to enroll patients with unresectable Merkel cell carcinoma that is local-regional or metastatic. II. Determine the overall survival rate and objective response rate of these patients after treatment with cyclophosphamide, methotrexate, and fluorouracil.
OUTLINE: Patients are stratified according to local-regional disease versus metastatic disease. Patients receive cyclophosphamide IV, methotrexate IV, and fluorouracil IV on day 1. Courses repeat every 21 days for up to 2 years in the absence of diseas...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Histologically proven unresectable Merkel cell carcinoma Local-regional OR Metastatic Bidimensionally measurable disease If all known sites previously irradiated, disease must be progressive CNS metastases allowed if not only site of measurable disease No pleural effusions or ascites
- • PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1500/mm3 Platelet count at least 100,000/mm3 Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception No other prior malignancy within 5 years except: Adequately treated basal cell or squamous cell skin cancer Adequately treated stage I or II cancer In situ cervical cancer
- • PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy or immunotherapy No concurrent immunotherapy Chemotherapy: No prior chemotherapy for metastatic disease At least 4 weeks since prior adjuvant chemotherapy No prior adjuvant cyclophosphamide, methotrexate, or fluorouracil No other concurrent chemotherapy Endocrine therapy: No concurrent hormone therapy Radiotherapy: See Disease Characteristics At least 14 days since prior radiotherapy Surgery: At least 2 weeks since prior surgery
About Swog Cancer Research Network
The SWOG Cancer Research Network is a leading cancer clinical trial organization dedicated to improving cancer treatment and outcomes through innovative research. Comprising a collaborative network of academic institutions, community hospitals, and cancer centers, SWOG conducts rigorous clinical trials that advance the understanding of cancer biology, prevention, and therapy. With a strong emphasis on inclusivity and diversity, SWOG aims to ensure that clinical research reflects the populations affected by cancer, ultimately striving to enhance patient care and quality of life. Through its commitment to scientific excellence and collaboration, SWOG plays a pivotal role in shaping the future of oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oklahoma City, Oklahoma, United States
Tucson, Arizona, United States
Ann Arbor, Michigan, United States
Los Angeles, California, United States
Los Angeles, California, United States
Denver, Colorado, United States
Lexington, Kentucky, United States
Detroit, Michigan, United States
Jackson, Mississippi, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Spartanburg, South Carolina, United States
Sacramento, California, United States
Wichita, Kansas, United States
New Orleans, Louisiana, United States
Phoenix, Arizona, United States
Atlanta, Georgia, United States
Kansas City, Missouri, United States
San Francisco, California, United States
Maywood, Illinois, United States
Mobile, Alabama, United States
Long Beach, California, United States
Los Angeles, California, United States
Martinez, California, United States
Oakland, California, United States
Santa Rosa, California, United States
Travis Air Force Base, California, United States
Lexington, Kentucky, United States
New Orleans, Louisiana, United States
Jamaica Plain, Massachusetts, United States
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
Saint Louis, Missouri, United States
Springfield, Missouri, United States
Billings, Montana, United States
Columbus, Ohio, United States
Dayton, Ohio, United States
Kettering, Ohio, United States
Portland, Oregon, United States
Greenville, South Carolina, United States
Galveston, Texas, United States
Seattle, Washington, United States
Albuquerque, New Mexico, United States
Temple, Texas, United States
Honolulu, Hawaii, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Little Rock, Arkansas, United States
Denver, Colorado, United States
Fort Gordon, Georgia, United States
Decatur, Illinois, United States
Hines, Illinois, United States
Wichita, Kansas, United States
Shreveport, Louisiana, United States
Shreveport, Louisiana, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Southfield, Michigan, United States
Biloxi, Mississippi, United States
Jackson, Mississippi, United States
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Cincinnati, Ohio, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
San Antonio, Texas, United States
Temple, Texas, United States
Salt Lake City, Utah, United States
Seattle, Washington, United States
Seattle, Washington, United States
Tacoma, Washington, United States
Phoenix, Arizona, United States
Kansas City, Kansas, United States
New Orleans, Louisiana, United States
Grand Rapids, Michigan, United States
Keesler Afb, Mississippi, United States
Portland, Oregon, United States
Fort Sam Houston, Texas, United States
Lubbock, Texas, United States
Salt Lake City, Utah, United States
San Antonio, Texas, United States
Brooklyn, New York, United States
Patients applied
Trial Officials
Raymond A. Kempf, MD
Study Chair
University of Southern California
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials